CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 268 enrolled
Drug / intervention
Cannabis Edibledrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03522324
NCT03522324N/ACompleted

An Observational Study of the Effects of Edible Cannabis and Its Constituent Cannabinoids on Pain, Inflammation, and Cognition

University of Colorado, Boulder·observational·Posted May 11, 2018·Updated Aug 27, 2025

In Brief

An observational study evaluating Cannabis Edible for Chronic Pain and 2 related conditions. Completed, enrolled 268 participants across 1 site.

Detailed Summary

This study tests the effects of cannabinoid levels in blood on pain relief, inflammation, and cognitive dysfunction in chronic pain patients who choose to use edible cannabis. Over a two-week period, participants use an edible product of their choice. Blood levels of 9-delta-tetrahydrocannabinol (THC) and cannabidiol (CBD) will be measured before, during, and after the two-week exposure period to determine whether there are associations with pain, inflammation, sleep, physical activity, anxiety/depression, and cognitive dysfunction. After the two-week self-administration period, participants will be followed for six months to collect self-report data on cannabis use, pain levels, sleep quality, and mental health symptoms.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedMay 11, 2018
Enrollment StartJun 1, 2018
Primary CompletionApr 10, 2023
Study CompletionOct 12, 2023
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 8.1 years ago

Interventions

Cannabis Edibledrug

Self-Directed Use (ad-libitum)